Tango Reports Promising Phase 1/2 Data for Pancreatic Cancer Combination
Tango Therapeutics reported promising Phase 1/2 clinical data for its pancreatic cancer therapy, announcing plans to initiate a pivotal Phase 3 study in 2027 and a strong cash balance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed